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Abstract: c-Jun N-terminal kinase (JNK) is upregulated during multiple sclerosis relapses and at
the peak of experimental autoimmune encephalomyelitis (EAE). We aim to investigate the effects of
pharmacological pan-JNK inhibition on the course of myelin oligodendrocyte glycoprotein (MOG35-55)
EAE disease using in vivo and in vitro experimental models. EAE was induced in female C57BL/6JRj
wild type mice using MOG35-55. SP600125 (SP), a reversible adenosine triphosphate competitive
pan-JNK inhibitor, was then given orally after disease onset. Positive correlation between SP plasma
and brain concentration was observed. Nine, but not three, consecutive days of SP treatment led
to a significant dose-dependent decrease of mean cumulative MOG35-55 EAE severity that was
associated with increased mRNA expression of interferon gamma (INF-γ) and tumor necrosis
factor alpha (TNF-α) in the spinal cord. On a histological level, reduced spinal cord immune
cell-infiltration predominantly of CD3+ T cells as well as increased activity of Iba1+ cells were
observed in treated animals. In addition, in vitro incubation of murine and human CD3+ T cells with
SP resulted in reduced T cell apoptosis and proliferation. In conclusion, our study demonstrates that
pharmacological pan-JNK inhibition might be a treatment strategy for autoimmune central nervous
system demyelination.
Keywords: multiple sclerosis; immunotherapy; mitogen-activated protein kinases; MAPK;
SP600125; neuroinflammation
1. Introduction
Multiple sclerosis (MS) is an inflammatory and degenerative disorder of the central nervous system
(CNS) [1]. Mitogen-activated protein kinases (MAPKs) have been shown to be involved in the regulation
of cytokine gene expression, immune cell differentiation, neuronal-cell-death pathways and regulation
of astrocyte inflammatory genes [2,3]. Consequently, they might influence both pathomechanisms of
MS; neuroinflammation and degeneration. More precisely, MAPKs are divided into three subfamilies:
The c-Jun N-terminal kinases (JNKs), the extracellular signal-regulated kinases (ERKs) and the p38
mitogen-activated protein kinases (p38) [4]. Originally, JNKs were named stress-activated protein
kinases (SAPKs) due to their ability to respond to different environmental stressors such as ultraviolet
irradiation, osmotic shock or oxidative stress [5]. Later, it was demonstrated that cytokines, hormones
or morphogenic factors were also able to activate the c-Jun N-terminal kinase (JNK) pathway [6].
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In mammals, three Jnk genes have been described. Of these, Jnk1 and Jnk2 are ubiquitously expressed,
whereas Jnk3 is exclusively found in heart, brain and testis [7].
The JNK pathway has been proposed to be an important player in several neurological and
autoimmune disorders [8,9], and particular in MS where upregulation of JNK activity has been
observed in peripheral blood mononuclear cells (PBMCs) of relapsing MS patients compared to healthy
volunteers [10]. Moreover, an increase of phosphorylated JNK (p-JNK) was found in the spinal cords
of myelin basic protein (MBP) experimental autoimmune encephalomyelitis (EAE) Lewis rats during
the acute phase of the disease [11]. Non-specific as well as specific inhibition of the JNK pathway has
also demonstrated some beneficial effects in the myelin oligodendrocyte glycoprotein (MOG35-55) EAE.
For instance, N-acetylcysteine amide (AD4), a copper chelator, attenuates MOG35-55 disease severity by
scavenging reactive oxygen species, by reducing matrix metallopeptidases activation and by inhibiting
p38 and JNK phosphorylation [12]. It has also been shown that Paeoniflorin, which is extracted from
the roots of Paeonia lactiflora, ameliorates MOG35-55 EAE disease severity by decreasing Th17 cell
differentiation and by inhibiting dendritic cell function via the suppression of the IKK/NFkB and JNK
pathway [13]. In addition, preventive treatment with SP600125 (SP), a JNK inhibitor, reduces the
MOG35-55 EAE disease severity in wild type (WT) mice [14]. However, the genetic knockout of Jnk2 did
not lead to differences in MOG35-55. EAE disease course compared to wild type C57BL/6JRj (C57BL/6)
mice [15], whereas knockout of Jnk1 moderately ameliorated EAE disease course [16].
A mouse model with a pan-JNK knockout as well as studies investigating the treatment effect of
a pharmacological pan-JNK inhibition in a therapeutic setting are lacking.
Therefore, our goal was to investigate, whether pharmacological inhibition of all JNK isoforms in
a therapeutic setting may have the potential to ameliorate MOG35-55 EAE disease course. Given positive
findings in vivo, we further aimed at subsequently translating the results to the human situation by
performing in vitro studies in murine and human CD3+ T cells in parallel.
2. Materials and Methods
Animal and human studies were approved by the local authorities (Office of Agriculture and Nature
Bern, Switzerland: 101/16; Cantonal Ethic Committee Bern, Switzerland: 2017-00060). C57BL/6JRj
(C57BL/6) WT mice were ordered from Janvier Labs (Le-Genest-Saint-Isle, France) and housed under
conventional housing conditions at the in-house animal facility of the University of Bern.
2.1. In Vivo and In Vitro Treatments
JNK inhibition was performed using SP600125 (SP), a pan-JNK inhibitor (Seleck Chemicals,
Houston, TX, USA). SP was chosen for our experiments as it is a non-toxic reversible adenosine
triphosphate (ATP) competitive inhibitor of JNK with similar specificity especially for the immunological
relevant JNK isoforms 1 and 2 [17]. SP concentration used for the in vitro experiments was set to 10 µM
and for in vivo experiments to 15 and 30 mg/kg/day.
2.2. Active Myelin Oligodendrocyte Glycoprotein (MOG35-55) Experimental Autoimmune Encephalomyelitis
(MOG35-55 EAE)
Active MOG35-55 EAE was induced in 8 weeks old female C57BL/6 WT mice following our
previously described MOG35-55 EAE induction protocol [18]. Briefly, animals were immunized by
subcutaneous injection of 100 µg MOG35-55 peptide (Institute of Medical Immunology, Charité, Berlin,
Germany) in phosphate-buffered saline solution (PBS; Thermo Fisher Scientific, Dreieich, Germany)
emulsified in complete Freund’s adjuvant containing 100 µg mycobacterium tuberculosis (Difco,
Detroit, MI, USA), followed by 200 ng pertussis toxin (Quadratech, Epsom, UK; intraperitoneal (i.p.)
injection, days 0 and 2). Animals were scored daily in a blinded manner using a 10-point EAE scale [18].
In addition to EAE scoring, body weight, which is a well-established parameter of drug side effects [19],
was measured daily and a clinical assessment of side effects based on body weight and observation
of the animals’ behavior was performed. Treatment was initiated when animals had an EAE score
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≥2. SP (15 or 30 mg/kg/day (Sigma-Aldrich, MO, USA), solvent: Dimethyl sulfoxide (DMSO, final
DMSO (Sigma-Aldrich) concentration 10% in peanut oil (Migros, Zurich, Switzerland)) oral gavage;
and control (10% DMSO in peanut oil, oral gavage) were given on three or nine consecutive days.
2.3. Apoptosis Assay
CD3+ T cells were isolated from the spleen of C57BL/6 WT mice or from human PBMCs sampled
from healthy donors by negative magnetic-activated cell sorting (MACS) selection (Pan-T cell isolation
kit®, Miltenyi Biotec, NRW, Germany). CD3+ T cells were resuspended at 1mio/ml in T cell medium
(RPMI 1640 medium, Life Technologies, CA, USA) containing 10% fetal bovine serum (FBS, Life
Technologies), 1% penicillin/streptomycin (P/S, Thermo Fisher Scientific) and 1% L-glutamine (Life
Technologies)). Cells were plated in a round bottom 96-well plate at a concentration of 100 000 cells/well.
Murine CD3+ T cells were stimulated with concanavalin A (conA, 1.5 µg/mL, Sigma-Aldrich) and
human CD3+ T cells with phytohemagglutinin (PHA, 2.5 µg/mL, Sigma-Aldrich). Both murine and
human CD3+ T cells were treated with SP (10 µM, dissolved in DMSO, final DMSO concentration in
the experiment 0.1%). Apoptosis (Annexin V/Propidium iodide, Becton Dickinson Bioscience, NJ, USA)
was analyzed by flow cytometry after 24 h for murine and 72 h for human CD3+ T cells, respectively.
2.4. Proliferation Assay
Murine and human CD3+ T cells were isolated and cultivated as described in the subsection
apoptosis assay. Murine cells were collected after 48 h and human cells after 72 h and proliferation
was assessed by flow cytometry using carboxyfluorescein succinimidyl ester staining (CFSE, Thermo
Fisher Scientific).
2.5. RNA Isolation
Splenic-derived CD3+ T cells, spinal cords and brains were isolated from control (CD3+ T cells
and spinal cords: n = 5; brains: n = 9) or SP-treated (CD3+ T cells and spinal cords: n = 5; brains: n = 9;
30 mg/kg/day) mice at peak of MOG35-55 EAE disease corresponding to day 4 after treatment initiation
(for disease course and body weight of the mice see Figures A1 and A2). RNA was extracted following
manufacturer’s instructions (RNeasy Kit, Qiagen, Hilden, Germany). Complementary DNA (cDNA)
was prepared from 1 µg RNA mixed with Quanta qScript cDNA SuperMix (VWR International, Radnor,
PA, USA). Reverse transcription was done using a thermal program of 5 min 25 ◦C, 30 min 42 ◦C and 5
min 85 ◦C. RNA was stored at −80 ◦C.
2.6. Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) and Analysis
Expression of interferon gamma (INF-γ), tumor necrosis factor alpha (TNF-α), interleukin-4
(IL-4), interleukin-10 (IL-10) and interleukin-17 (IL-17) genes was analyzed using qRT-PCR with
primers from Thermo Fisher Scientific (INF-γ: Mm01168134_m1; TNF-α: Mm00443258_m1; IL-4:
Mm445259_m1; IL-10: Mm01288386_m1; and IL-17: Mm00439618_m1). Transcripts were amplified
using TaqMan qRT-PCR (TaqMan universal mastermix: KAPPA PROBE FAST Universal, Sigma-Aldrich,
Louis, MO, USA). Experiments were run on an ABI7500 (Applied Biosystems, Foster City, CA, USA).
Gene expression was normalized to housekeeping gene Rps18 coding for the Ribosomal Protein S18
(Mm02601777_g1, Thermo Fisher Scientific). The standard curve method of comparative quantification
was used to analyze results [20].
2.7. Protein Analysis
Spinal cords and brains were isolated from control (n = 9) or SP-treated (n = 9, 30 mg/kg/day) mice at
peak of MOG35-55 EAE disease corresponding to day 4 after treatment initiation (for disease course and
body weight of the mice see Figure A2). Proteins were extracted following manufacturer’s instructions
(Tissue Extraction Reagent I, Invitrogen, CA, USA). INF-γ and TNF-α protein concentrations were
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measured using commercially available ELISA kits (INF-γ: ab100690, Abcam, Cambridge, UK; TNF-α:
88-7324, Invitrogen).
2.8. Histology
Spinal cords were isolated from control (n = 9) or SP-treated (n = 9, 30 mg/kg/day) mice at peak
of MOG35-55 EAE disease corresponding to day 4 after treatment initiation (for disease course and
body weight of the mice see Figure A2), dehydrated and embedded in paraffin. Then, 5 µm thick
tissue sections were stained with hematoxylin and eosin (H&E) or luxol fast blue/periodic acid Schiff.
CD3+ and Mac3+ cells were detected via immunohistochemistry, whereas GFAP+ and Iba1+ cells
were visualized after immunofluorescence staining (CD3 (primary antibody): Rat-α-human CD3,
1:100, AbD Serotec, Düsseldorf, Germany; Mac3 (primary antibody): Rat-α-mouse Mac3, 1:100; BD
Pharmingen, Heidelberg, Germany; CD3 and Mac3 (secondary antibody): Biotinylated rabbit-α-rat
IgG, 1:200, Vector Labs, CA, USA; GFAP (primary antibody): Chicken-α-GFAP, 1:1000, Abcam; GFAP
(secondary antibody): Goat-α-chicken AF488, 1:1000, Thermo Fisher; and Iba1 (primary antibody):
Rabbit-α-Iba1, 1:200, Wako, Osaka, Japan; Iba1 (secondary antibody): Goat-α-rabbit AF555, 1:1000,
Thermo Fisher). Images were acquired with a slide scanner (Pannoramic 250 Flash III, 3DHISTECH,
Budapest, Hungary). For each spinal cord segment (cervical, thoracic and lumbar), four different
regions of interest (ROI) were examined except for demyelination where the complete white matter
was analyzed. CD3+ and Mac3+ cell infiltrations were determined using CaseViewer (3DHISTECH).
The percentage of white matter demyelination, GFAP and Iba1 fluorescence intensity as well as the
roundness of Iba1+ cells were determined with ImageJ (National Institute of Mental Health, NIH,
Bethesda, MD, USA).
2.9. Mass Spectrometry
The liquid chromatography–mass spectrometry (LC-MS) system with an autosampler was
a Shimadzu LC-20A (Shimadzu, Japan) coupled with Applied Biosystem Sciex (MDS Sciex, Canada)
API 5500 Tandem quadrapole mass spectrometer. The autosampler was SIL-HTC and the LC pump
was LC-20AD, both from Shimadzu. The chromatographic integration was performed by Analyst
software (version: 1.6.3; Applied Biosystems). Chromatographic separation was performed on a
Phenomenex Kinetex C18 2.6u 2.1 by 50 mm analytical column and the mobile phase was 0.1% (v/v)
formic acid in water and 0.1% (v/v) formic acid in acetonitrile with a gradient, injection volume of 6 µL
and flow rate of 0.4 mL/min. Total analysis time of a single injection was 3 minutes and 30 seconds.
Column oven temperature and autosampler temperature was set to 25 ◦C and 6 ◦C, respectively.
The LC eluent was introduced via electrospray ionization using a Turbo IonSpray interface set at
600 ◦C to generate positive ions [M+H] +. Ionization was assisted with nebulizer and IonSpray gas
(nitrogen) at 7 (arbitrary units) and 10 L/min, respectively. The IonSpray potential was maintained at
5 kV. During ms/ms analysis, the collision energies used ranged from 25 to 37 V and the scan speed was
10 Da/sec. Quantification was performed by multiple reaction monitoring of the protonated precursor
ion and the related product ion for both test article and internal standard (IS, propranolol) using the
IS method with a peak area ratio and a linear least-squares regression curve with weighting factor
of 1/×2. The mass transitions used for test article and propranolol were m/z 221.0→165.0 and m/z
260.2→116.2, respectively.
Stock solutions of test article and propranolol were prepared in DMSO and further diluted in
ethanol. Calibration standards of eight concentration levels were prepared freshly and spiked into
drug-free plasma or brain homogenate with test article stock solutions to give concentrations of 0.00116,
0.00231, 0.00463, 0.0139, 0.0417, 0.125, 0.500 and 2.0 µM.
Brain samples (accurately weighed) were homogenized to a final dilution of 3× (w/v) in 50:50
methanol:water using ceramic beads. Vigorous shaking and rotation at high revolution (known as bead
blasting) of the brain and diluent against the metal beads inside a capped sample tube disrupts the
cellular structure and effects homogenization of individual samples with zero carryover in preparation,
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as the beads are only used once. Blank brain samples were treated in the same manner and used for
the calibration curve matrix.
Plasma and brain homogenates were aliquoted and the test article was extracted via protein
precipitation with 5 volumes of acetonitrile containing 20 nM propranolol as the internal standard
vortexed for 5 minutes, followed by centrifugation at 4000 rpm/min on a cooling centrifuge for
10 minutes at 25 ◦C. The supernatant was withdrawn and diluted 1:1 with LC-MS grade water before
injection on the LC-MS system. The limit of quantification was of 1.16 nM.
2.10. Statistical Analysis
Data are expressed as mean +/− standard error of the mean (SEM). Comparison of data was
performed using Kruskal–Wallis Test (KWT) or Mann–Whitney test (MWT), depending on the number
of group comparisons, for independent and Wilcoxon signed rank sum test (WSRST) for dependent
measurements. Association between SP serum and brain tissue concentration was analyzed using
Pearson correlation coefficient. Gene expression and protein data were calculated as X-fold change of
SP compared to control-treated animals and plotted as mean and 95%-confidence interval (95%-CI).
In this analysis—as 1-fold represents no significant difference—a one-sample t-test (OSTT) was used
with the test value of 1 to investigate gene regulation by SP. To determine if EAE score or cumulative
SP dose influence body weight, a multivariate linear regression analysis was run. In this regression
models, body weight at end of disease was used as dependent variable and EAE score, dose group of
SP and an interaction term between the latter as independent variables. Data of the regression analysis
is given as coefficient (coef) and 95%-CI. Significance was assumed for all tests if p-value was <0.05.
3. Results
3.1. Plasma and Brain SP Concentrations of SP 30 mg/kg/day-Treated Acute MOG35-55 EAE-Diseased Mice
Positively Correlate
Preliminary data using a small cohort demonstrated that SP was detectable in the plasma of
5/6 and in the brain of 4/6 SP 30 mg/kg/day-treated acute MOG35-55 EAE-diseased mice, whereas it
was undetectable in all four control mice. In more details, the mean plasma SP concentration of SP
30 mg/kg/day-treated acute MOG35-55 EAE-diseased mice was of 3.35 nM (SEM 0.45, n = 5), whereas
the mean SP brain concentration was of 8.62 nM (SEM 2.46, n = 4). Furthermore, positive correlation
between SP plasma and brain concentration was noticed (Pearson r correlation, coefficient 0.97, 95% CI:
0.19–1.0, p < 0.05, Figure 1).
Figure 1. Association between plasma and brain SP600125 (SP) concentration. SP concentration was
measured both in the plasma and in the brain of SP 30 mg/kg/day-treated acute myelin oligodendrocyte
glycoprotein (MOG35-55) experimental autoimmune encephalomyelitis (EAE)-diseased mice (n = 4).
n = 2 pairs had no detectable values in brain or plasma samples and were excluded. Mass spectrometry.
Abbreviations: SP: SP600125. Statistic: Pearson r correlation, coefficient 0.97, 95% CI: 0.19-1.0
and p < 0.05.
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3.2. Effects of Pharmacological Pan-JNK Inhibition on MOG35-55 EAE Disease Course
Two experimental setups were used to evaluate if pan-JNK inhibition is a potential strategy for
treatment of acute demyelinating events: Drug administration over three consecutive days in analogy
to treatment of MS relapses in the human setting versus drug administration over nine consecutive
days imitating chronic treatment of autoimmune neuroinflammation. Short-term treatment over three
consecutive days with either 15 or 30 mg/kg/day had no effect on the mean cumulative MOG35-55 EAE
score (KWT: Each p > 0.05; Figure 2A) and on body weight (KWT: Each p > 0.05; Figure 2B). In contrast,
administration over nine consecutive days led to a reduction of mean cumulative MOG35-55 EAE score
in the SP 15 mg/kg/day group by 24.0% (KWT: p < 0.0001; Figure 2C) and in the 30 mg/kg/day group
by 43.3% (KWT: p < 0.0001; Figure 2C) compared to control treatment. This reduced clinical severity
was accompanied by higher body weights of the 15 and 30 mg/kg/day SP-treated animals (mean
percentage of body weight changes compared to control: SP 15 mg/kg/day +0.9% (KWT: p > 0.05) and
SP 30 mg/kg/day +4.3% (KWT: p < 0.0001); Figure 2D).
In both experimental setups and treatment arms, no SP side effects on gross animal behavior
were observed. Multivariate regression analysis demonstrated that weight loss was independent of
treatment (3 days treatment: Coefficient −0.12 95%-CI -0.32–0.07, p = 0.21; 9 days treatment: Coefficient
0.02 95–%CI −0.11–0.16; p = 0.70), but predicted by MOG35-55 EAE score in the control as well as the SP
groups (3 days treatment: Coefficient −4.7 95%-CI −5.2–−4.2, p < 0.001; 9 days treatment: Coefficient
−8.1 95%–CI −9.1–−7.1; p < 0.001).
3.3. JNK Inhibition Increases Spinal Cord INF-γ and TNF-α mRNA Expression during the Acute Phase of
MOG35-55 EAE
In spinal cord, SP treatment (30 mg/kg/day) led to a 2.4-fold increased mRNA expression of IFN-γ
and a 2.1-fold increase of TNF-α mRNA expression compared to control mice in the acute phase of
MOG35-55 EAE (OSST (test value 1): p < 0.05; Figure 3A), whereas IL-4, IL-10 and IL-17 were not
differentially regulated (OSST (test value 1): Each p-value > 0.05; Figure 3A). No significant different
mRNA expression of INF-γ and TNF-α was observed in the brains of SP-treated acute MOG35-55
EAE-diseased mice compared to control mice (OSST (test value 1): p > 0.05, Figure A3). Spinal cord
and brain protein expression of INF-γ also did not significantly differ between the two groups (OSST
(test value 1): p > 0.05, Figure A4). In splenic-derived CD3+ T cells, no differential cytokine mRNA
expression between SP (30 mg/kg/day) and control treatment was detected (OSST (test value 1): Each p
> 0.05; Figure 3B). Clinical disease course and body weight of the mice used for these experiments are
shown in Figures A1 and A2.
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Figure 2. Clinical disease course of MOG35-55 EAE in C57BL/6JRj wild type mice treated for (A) three
or (C) nine consecutive days with control (dimethyl sulfoxide (DMSO (in peanut oil), SP600125 15 or
30 mg/kg/day. Body weight during course of MOG35-55 EAE in C57BL/6JRj wild type mice treated for
(B) three or (D) nine consecutive days with control (DMSO in peanut oil), SP600125 15 or 30 mg/kg/day.
Numbers of included animals are displayed in the graph. EAE score: 10 score system according to [18].
Abbreviations: EAE: Experimental autoimmune encephalomyelitis, SEM: Standard error of the mean
and SP: SP600125. Statistic: Kruskal–Wallis Test: ### < 0.001 and #### < 0.0001.
Figure 3. Effect of SP treatment on relative cytokine mRNA expression in (A) murine spinal cord
of MOG35-55 EAE-diseased mice (acute phase) and in (B) murine splenic-derived CD3+ T cells of
MOG35-55 EAE-diseased mice (acute phase). (A,B) X-fold difference in the relative expression of INF-γ,
TNF-α, IL-4, IL-10 and IL-17 (normalized to Rps18) in SP 30 mg/kg/day-treated mice compared to
control mice. Control (n = 5, in triplicates), SP 30 mg/kg/day (n = 5, in triplicates) and 3 days of
treatment. qRT-PCR. Abbreviations: SP: SP600125, CI: Confidence of interval. Statistic: One-sample
t-test # < 0.05.
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3.4. JNK Inhibition Reduces Spinal Cord Cell-Infiltration during the Acute Phase of MOG35-55 EAE
SP 30 mg/kg/day-treated acute MOG35-55 EAE-diseased mice showed a significant reduced spinal
cord CD3+ T cell infiltration compared to control mice (MWT, p < 0.01, Figure 4A). This reduced
CD3+ T cell infiltration is pronounced when looking at the cervical segment of the spinal cord (MWT,
p < 0.0001, Figure A5A). A trend at a 90% level of significance of a reduced Mac3+ cell infiltration in
the overall spinal cord was also observed (MWT, p = 0.07, Figure 4B) which was driven by the cervical
segment (MWT, p < 0.0001, Figure A5B). Significant increase of Iba1 fluorescence intensity, as well
as a significant increase in the roundness of the Iba1+ cells was noticed in the lumbar segment of
the spinal cord (MWT, p < 0.05, Figure A6A–B) but no significance was observed when looking at
the overall spinal cord (MWT, p > 0.05, Figure 4C–D). No significantly different GFAP fluorescence
intensity was observed between the two groups, neither in all nor in a specific segment (MWT, p > 0.05,
Figures 4E and A6C). Furthermore, no significant difference in white matter demyelination was noticed
between the two groups (MWT, p > 0.05, Figures 4F and A5C).
Figure 4. Effect of SP treatment on murine spinal cord (A) CD3+ cell infiltration, (B) Mac3+ cell
infiltration, (C) Iba1 fluorescence intensity, (D) Iba1+ cell roundness, (E) GFAP fluorescence intensity
and (F) white matter demyelination. Spinal cords were extracted from control or SP 30 mg/kg/day-treated
MOG35-55 EAE-diseased mice (acute phase). Three segments of each spinal cord (cervical, thoracic
and lumbar) were evaluated and pooled. For each segment, four different regions of interest were
analyzed except for demyelination where the complete white matter was analyzed. Control (n
= 9), SP 30 mg/kg/day (n = 9) and 3 days of treatment. (A–B) immunohistochemistry, (C–E)
immunofluorescence and (F) luxol fast blue staining. Each dot represents a measurement. Orange dots
show measurements of the cervical segment, green of the thoracic segment and blue of the lumbar
segment of the spinal cord. Abbreviations: SC: Spinal cord, SEM: Standard error of the mean, SP:
SP600125 and WM: White matter. Statistic: Mann–Whitney test, ## < 0.01.
3.5. JNK Inhibition Exerts Anti-Apoptotic and Anti-Proliferative Effects in Murine and Human CD3+ T Cells
SP administration reduced apoptosis and proliferation of CD3+ T cells from C57BL/6 WT mice and
human healthy donors in vitro: Incubation of murine CD3+ T cells with SP 10µM resulted in a reduction
of apoptosis by 5% compared to control (WSRST: p < 0.05; Figure 5A) and reduced proliferation by 15%
(WSRST: p < 0.01; Figure 5B). Results in the human situation were more pronounced with a reduction
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of CD3+ T cell apoptosis by21% (WSRST: p < 0.001; Figure 5C) and decreased proliferation by 91%
(WSRST: p < 0.001; Figure 5D).
Figure 5. (A,C) apoptosis of CD3+ T cells of C57BL/6JRj mice (A, n = 4 experiments in triplicates,
stimulus concanavalin A (conA) 1.5 µg/mL, 24 h) and healthy human controls (C, n = 7 experiments
in triplicates, stimulus phytohemagglutinin (PHA) 0.5 µg/mL, 72 h). Incubation with control or SP
10 µM (Annexin V/PI, flow cytometry). (B,D) proliferation of CD3+ T cells of C57BL/6JRj mice (B, n
= 4 experiments in triplicates, stimulus conA 1.5 µg/mL, 24 h) and healthy human controls (D, n =
7 experiments in triplicates, stimulus PHA 0.5 µg/mL, 72 h). Incubation with control or SP 10 µM
(CFSE, flow cytometry). Abbreviations: SEM: Standard error of the mean and SP: SP600125. Statistic:
Wilcoxon signed rank test # < 0.05, ## < 0.01 and ### < 0.001.
4. Discussion
Using two different in vivo treatment regimens, our study demonstrated that pharmacological
pan-JNK inhibition ameliorates MOG35-55 EAE disease course when administered after disease onset
over nine consecutive days in a therapeutic setting. Effects of pan-JNK inhibition appear to be mediated
by inhibition of CD3+ T cell proliferation and apoptosis in the peripheral immune compartment and
by regulation of cytokine expression and cell infiltration in the CNS (Figure 6).
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Figure 6. Graphical abstract summarizing key experiments and results of this study. Abbreviations:
conc.: Concentration, EAE: Experimental autoimmune encephalomyelitis, expr.: Expression, sign.:
Significant, SC: Spinal cord, SP: SP600125 and PBMCs: Peripheral blood mononuclear cells. This
figure was created using Servier Medical Art templates licensed under a Creative Commons License
(https://creativecommons.org/licenses/by/3.0/).
Clinical effects were detected in MOG35-55 EAE experiments using SP, a pharmacological pan-JNK
inhibitor, given over nine consecutive days after disease onset. These findings contradict results of
studies with JNK isoform-specific knockout models, which failed to demonstrate a significant impact on
MOG35-55 EAE disease course [6]. Considering that JNK1 and JNK2 have important, but overlapping
functions [6], clinical effects of pharmacological pan-JNK inhibition with similar specificity for these two
isoforms [17] may explain these results, because reduced activity of one isoform cannot be compensated
by increased activity of the other. Taking into account that a Jnk-1/Jnk-2 double knockout has a lethal
phenotype [21], drug safety of our pharmacological approach has to be addressed carefully. In this
regard, our treatment regimen during either three or nine days of SP administration demonstrated no
clinical signs of SP side effects like a pronounced reduction of body weight, altered animal behavior
or even death. Regarding body weight as one parameter of drug toxicity [19], multivariate linear
regression analysis demonstrated that no MOG35-55 EAE score-independent negative effect of SP
treatment on body weight was present. Nevertheless, in addition to longer drug administration
and higher dosages, other parameters of drug toxicity like drug serum and tissue concentration,
hematological, liver and kidney parameters and daily food consumption should be investigated in the
future to accurately study the feasibility of a pharmacological pan-JNK inhibition in the light of drug
safety issues.
Plasma and brain tissue concentrations of SP were measured 24 h after the third oral gavage.
Preliminary results demonstrated a strong positive correlation (Pearson coefficient 0.97) between
plasma and brain SP concentration, indicating that SP crosses the blood-brain barrier. Concentrations
in the brain were approximately 2.6-fold higher than in the plasma, which might point to a favorable
CNS biodistribution of SP supporting the treatment efficacy in CNS disease.
Mechanistically, our study investigated cytokine regulation by SP during peak of MOG35-55 EAE
disease in the peripheral immune (splenic-derived CD3+ T cells) and CNS compartment (spinal cord
and brain). mRNA expression of Th1-derived cytokines (INF-γ, TNF-α), Th2-derived cytokines (IL-4),
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Th17-derived cytokines (IL-17) and regulatory cytokines (IL-10) were analyzed both in splenic-derived
CD3+ T cells and in the spinal cord of acute MOG35-55 EAE-diseased mice [22]. We observed an increased
mRNA expression of INF-γ and TNF-α in the spinal cord of SP 30 mg/kg/day-treated acute MOG35-55
EAE-diseased mice compared to control, whereas peripheral cytokine mRNA expression measured in
splenic-derived CD3+ T cells was not significantly regulated by SP. TNF-α and INF-γ are both known
to be secreted by different peripheral cells including T cells [23,24]. However, CNS-resident cells have
also been shown to produce these two types of cytokines [25,26] suggesting that these cell types could
be responsible for the observed increased mRNA expression of TNF-α and INF-γ in the spinal cord.
In contrast, spinal cord protein expression of INF-γ did not significantly differ between treatment
groups. However, this result does not contradict the previous one knowing that mRNA and protein
concentration do not necessarily correlate [27]. Moreover brain mRNA and protein expression of INF-γ
as well as brain mRNA of TNF-α were not affected by SP treatment, which is not surprising knowing
that the EAE driven inflammation mainly affects the spinal cord [28]. TNF-α protein expression
was also analyzed both in the spinal cord and brain of mice, however obtained values were below
the detection range of the ELISA kit (8 pg/ml) prohibiting further analysis. Increased expression of
INF-γ and reduced EAE disease severity has to be discussed in detail, as INF-γ was first described to
exacerbate EAE and MS [29]. However, there is increasing evidence that INF-γ has beneficial effects
on EAE, e.g., mice deficient for INF-γ or INF-γ receptor or mice treated with a neutralizing INF-γ
monoclonal antibody have a more severe EAE disease course [30]. These contradictory findings of
INF-γ can be explained using a dynamic model of INF-γ function under consideration of different
EAE disease phases. More precisely, it has been proposed that INF-γ promotes pathogenesis during
the initiation phase, whereas it suppresses the disease during the acute phase [31,32]. Translated to our
work, the finding of increased INF-γ expression in spinal cord during the acute phase of MOG35-55
EAE might represent one molecular mechanism, which finally leads to a less severe disease course in
SP-treated mice. In addition to INF-γ expression, TNF-α mRNA expression was upregulated in the
spinal cord during the acute phase in SP 30 mg/kg/day-treated MOG35-55 EAE-diseased mice. The role
of TNF-α in both EAE and MS is a matter of a controversial discussion. On one side, TNF inhibition
has beneficial effects in EAE [33] and TNF receptor I deficiency leads to delayed EAE onset [34]. On the
other side, results of a clinical trial using TNF inhibitor in MS patients were negative as MS disease was
even worse in the treatment arm [35]. It has been demonstrated that mice lacking TNF show severe
neurological impairment with extensive demyelination [36], and mice lacking the TNF receptor II have
an increased disease severity [37]. Another study demonstrated the importance of differentiating the
soluble and the membrane form of TNF with a detrimental role of soluble TNF and a beneficial role of
the transmembrane TNF in EAE. In detail, they showed that soluble TNF enhances the production of
pro-inflammatory mediators, whereas transmembrane TNF diminishes their production in CNS tissues
at the peak of EAE disease [38]. In our study, the observed clinical effect of SP is associated with an
increased TNF-α expression in the spinal cord during the acute phase of EAE disease, suggesting that
increased TNF-α expression is associated with beneficial effects of SP treatment. However, a limitation
of our study is that we are not able to differentiate between membrane-bound and soluble form of TNF
by only analyzing the gene expression [25].
Several hallmarks such as T cell and macrophage CNS infiltration, demyelination or astrocyte and
microglia activation characterize the EAE [39]. We observed a significant reduction of CD3+ T cell
infiltration in the whole spinal cord during the peak of the disease. In more details, stronger significant
reduction of CD3+ T cell infiltration was observed when looking at the cervical part of the spinal
cord. Despite it being still a matter of debate, various evidence points towards a role of JNK on T cell
activation/function [40–44]. We showed in vitro that JNK inhibition influences murine CD3+ T cell
proliferation and apoptosis, supporting our histological findings. There is sparse and inconclusive
evidence for effects of JNK inhibition on proliferation. Indeed, some demonstrated that SP reduces
T cell proliferation [17], whereas others observed no effect [45]. Regarding apoptosis, an influence
of the JNK pathway on pro- and anti-apoptotic mechanisms depending on cell type and stimulus
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is described [44]. Hypothetical, the functional effects of SP can be explained by the fact that T cell
apoptosis is reduced when anergy, expressed as lowest proliferation response, is maximal [46]. Anergic
T cells were shown to be defective in JNK signaling [47] and hindered JUN activation due to inhibited
autophagy [48]. Murine in vitro experiments were translated to the human situation, confirming that
in vitro effects of a pan-JNK inhibition were comparable between murine and human CD3+ T cells.
This gives experimental evidence that a pan-JNK inhibition might also be a potential treatment strategy
in human MS disease.
Reduced CD3+ T cell infiltration was accompanied by a decreased macrophage, defined as
Mac3+ cell, infiltration of the cervical part of the spinal cord. A beneficial effect of JNK inhibition on
macrophage infiltration has already been reported in other diseases. Indeed, reduced macrophage
infiltration into the colon has been observed in the dextran sulphate sodium (DSS)-induced colitis,
an animal model of inflammatory bowel diseases, when treated with SP [49]. In addition, it has been
demonstrated that activation of the JNK pathway was essential for the development and the survival of
macrophages [50]. Moreover, the effect of JNK inhibition on both GFAP and Iba1 fluorescence intensity
was analyzed. GFAP is commonly used to determine activated astrocytes [51,52], whereas Iba1 is
a marker for both macrophages and microglia [53]. Iba1 fluorescence intensity as well as morphological
analysis have been used to determine macrophage/microglia reactivity [54]. In our study, a significant
increase of Iba1 fluorescence intensity, as well as a significant increase in the roundness of the Iba1+
cell was noticed in the lumbar segment of the spinal cord, which hints at an increased activity of
microglia. Our findings are in line with previous data demonstrating that JNK inhibition with SP
changes inflammatory metabolic activity of microglia after external pro-inflammatory stimulus with
lipopolysaccharide in mice [55].
Despite effects on immune cell populations, we did not observe a statistically significant
difference in white matter demyelination between control and SP 30 mg/kg/day-treated acute MOG35-55
EAE-diseased mice. Nevertheless, the white matter demyelination was lower in SP-treated mice at
peak of disease (mean control mice: 24.8% (SEM 3.78); mean SP-treated mice: 20.5% (SEM 3.07)),
also reflecting reduced clinical MOG35-55 EAE severity in the SP treated animals. Indeed, c-Jun,
a downstream target of JNK, has previously been shown to negatively regulate myelination by
inhibiting different myelin genes and by favoring an immature state of the myelinating cells [56].
In our study, the effect of a pan-JNK inhibitor was analyzed and consequently no distinction
between the different isoforms was made. However, it is worthwhile to mention that several studies
point toward an important role of JNK3 inhibition in neuroprotection. Indeed, it has been observed
that mice with a neural-specific Jnk3 deletion are more resistant to glutamate excitotoxicity [57], which
has been shown to be deleterious in the EAE [58,59]. Furthermore, it has been shown that disruption of
the Jnk3 gene render mice less sensitive to brain injury after cerebral ischemia and that it prevents the
release of the cytochrome c from the mitochondria after oxygen-glucose deprivation [60]. Interestingly,
it has also been shown that both TNF- and TNF-related apoptosis-inducing ligand (TRAIL)-induced
death of mature adult human oligodendrocytes are mediated by JNK3 [61,62]. Consequently, further
investigations are warranted in order to define the therapeutic value of JNK inhibitors in MS better.
Findings of our experimental study should promote further investigations in the future taking into
account clinical effects, biological mechanisms of action as well as drug tolerability of pan-JNK inhibition.
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Appendix A
Figure A1. (A) clinical disease course of MOG35-55 EAE in C57BL/6JRj wild type mice treated for three
consecutive days with control (DMSO in peanut oil) or SP600125 30 mg/kg/day. (B) body weight during
course of MOG35-55 EAE in C57BL/6JRj wild type mice treated for three consecutive days with control
(DMSO in peanut oil) or SP600125 30 mg/kg/day. Numbers of included animals are displayed in the
graph. EAE score: 10 score system according to [18]. Abbreviations: EAE: Experimental autoimmune
encephalomyelitis, SEM: Standard error of the mean and SP: SP600125. Statistic: Mann–Whitney
Test: n.s.
Figure A2. (A) clinical disease course of MOG35-55 EAE in C57BL/6JRj wild type mice treated for three
consecutive days with control (DMSO in peanut oil) or SP600125 30 mg/kg/day. (B) body weight during
course of MOG35-55 EAE in C57BL/6JRj wild type mice treated for three consecutive days with control
(DMSO in peanut oil) or SP600125 30 mg/kg/day. Number of included animals are displayed in the
graph. EAE score: 10 score system according to [16]. Abbreviations: EAE: Experimental autoimmune
encephalomyelitis, SEM: Standard error of the mean and SP: SP600125. Statistic: Mann–Whitney Test:
# < 0.05 and #### < 0.0001.
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Figure A3. Effect of SP treatment on relative cytokine mRNA expression in murine brains of
EAE-diseased mice (acute phase). X-fold difference in the relative expression of interferon gamma
(INF-γ) and tumor necrosis factor alpha (TNF-α) (normalized to Rps18) in SP 30 mg/kg/day-treated
mice compared to control mice. Control (n = 9, in triplicates), SP 30 mg/kg/day (n = 9, in triplicates) and
3 days of treatment. qRT-PCR. Abbreviations: SP: SP600125 and CI: confidence of interval. Statistic:
one-sample t-test: n.s.
Figure A4. Effect of SP treatment on relative cytokine protein INF-γ expression in (A) murine spinal
cords and in (B) murine brains of EAE-diseased mice (acute phase). X-fold difference in the relative
expression of INF-γ in SP 30 mg/kg/day-treated mice compared to control mice. Control (n = 9,
in triplicates), SP 30 mg/kg/day (n = 9, in triplicates) and 3 days of treatment. ELISA. Abbreviations: SP:
SP600125 and CI: confidence of interval. Statistic: one-sample t-test: n.s.
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Figure A5. Effect of SP treatment on murine spinal cord (A) CD3+ cell infiltration, (B) Mac3+ cell
infiltration and (C) demyelination. Spinal cords were extracted from control or SP 30 mg/kg/day-treated
EAE-diseased mice (acute phase). Three segments of each spinal cord (cervical, thoracic and lumbar)
were evaluated. For each segment, four different regions of interest were analyzed except for
demyelination where the complete white matter was analyzed. Control (n = 9), SP 30 mg/kg/day (n = 9)
and 3 days of treatment. (A–B) immunohistochemistry and (C) luxol fast blue staining. Each dot
represents a measurement. Abbreviations: SC: spinal cord, SEM: standard error of the mean, SP:
SP600125 and WM: White matter. Statistic: Mann–Whitney test, #### < 0.0001.
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Figure A6. Effect of SP treatment on murine spinal cord (A) Iba1 fluorescence intensity, (B) Iba1+
cell roundness and (C) GFAP fluorescence intensity. Spinal cords were extracted from control or SP
30 mg/kg/day-treated EAE-diseased mice (acute phase). Three segments of each spinal cord (cervical,
thoracic and lumbar) were evaluated. For each segment, four different regions of interest were analyzed.
Control (n = 9), SP 30 mg/kg/day (n = 9) and 3 days of treatment. (A–C) immunohistochemistry. Each
dot represents a measurement. Abbreviations: SC: Spinal cord, SEM: Standard error of the mean and
SP: SP600125. Statistic: Mann–Whitney test, # < 0.05.
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